Primary HSV infection of the eye results in herpes simplex keratoconjunctivitis with latency established in the trigeminal nerve.
An Inquiry into the Molecular Basis of HSV Latency and Reactivation - Annual Review of ... - 3 views
-
-
I was wondering why the primary lit paper was doing there tests in corneal cells. I forgot that there is an HSV that infects the eyes. What exactly happens to the host cell once the virus is derepressed after latency? I'm sure it has said it in one or both of that papers, but I'm confused by the mechanism. The virus doesn't kill the host cell does it? Being that it resides in nerve cells (which is something new to me) and nerve cells don't replicate, killing the nerve seems like a bad idea for them and for us. Does the presence of the active virus (not latent virus) affect the function of the nerve? As in, does the herpes simplex keratoconjunctivitis affect the trigeminal nerve in that the virus interferes with the transmitting of sensory information from the face to the brain?
-
*Their tests
-
-
Notably, antibodies to HSV can routinely be detected in the cerebrospinal fluid of otherwise healthy individuals, implying that HSV can establish latency in the central nervous system and cause an adaptive immune response, as noted above by PCR data (24). It is unlikely that antibodies to HSV are passively transported across the intact blood-brain barrier.
BMC Cancer | Full text | Oncolytic Targeting of Androgen-sensitive Prostate Tumor by th... - 4 views
-
Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus (RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells.
- ...2 more comments...
-
How Oncolytic virus control the inflammation? - Oncolytic virus treatment induced at least a twofold increase or decrease in the expression of 50 genes relative to expression in the PBS-treated tumors (Supplementary Table 1, available online). Of these 50 genes, 48 displayed an increase in expression in the oncolytic virus - treated tumors compared with the controltreated tumors, suggesting that oncolytic virus treatment induced an inflammatory response - To confirm the role of the immune response in oncolytic virus - induced vascular hyperpermeability, we evaluated changes in oncolytic virus - induced vascular leakage in tumor-bearing rats that had been treated with cyclophosphamide before oncolytic virus injection. In addition to its immunosuppressive effects, cyclophosphamide blocks infl ammation and reduces viral clearance, both of which increase the propagation of oncolytic viruses, thereby enhancing therapeutic effi cacy of oncolytic viruses. (Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy, http://www.ncbi.nlm.nih.gov/pubmed?term=Effect%20of%20Tumor%20Microenvironment%20Modulation%20on%20the%20Efficacy%20of%20Oncolytic%20Virus%20Therapy)
-
PLOS Pathogens: Different Modes of Retrovirus Restriction by Human APOBEC3A and APOBEC3... - 22 views
-
One such family of restriction factors is the apolipoprotein B editing complex 3 (A3) cellular cytidine deaminases (CDA). While A3 genes are found in all mammals, their number differs from species to species. For example, humans have 7 A3 genes (A3A to A3H) while mice have only one gene. All proteins in this family contain at least one CDA domain that deaminates carbon 4 of cytidine in single-stranded DNA, resulting in a uracil that causes G to A transitions in the opposing strand [3].
-
viral cDNA accumulation
-
Packaging of A3G into virions is counteracted by HIV Vif (viral infectivity factor) protein. In virus-producer cells, Vif binds to A3G as well other A3 family members, and recruits cellular E3 ubiquitin ligase complexes, leading to ubiquitination and subsequent proteasomal degradation, thereby preventing packaging of A3G into budding virions [12]–[14]. Lentiviral Vif proteins show strong species-specificity. For example, HIV-1 Vif counteracts human A3G but only certain simian A3G homologues [15], [16]; it also does not interact with mouse A3 [17].
- ...12 more annotations...
1 - 5 of 5
Showing 20▼ items per page